Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Seven abstracts to be presented demonstrating treatment effects of Bylvay® in two cholestatic liver diseases, progressive familial intrahepatic cholestasis and Alagille syndrome Data to be... | June 12, 2023
Source: marketscreener.com